港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

银诺医药－Ｂ

51.300

-1.300-2.47%

成交量：41.62万

成交额：2,129.23万

市值：234.35亿

市盈率：-112.93

高：51.700

开：51.500

低：50.750

收：52.600

52周最高：74.000

52周最低：49.500

股本：4.57亿

香港流通股本：4.20亿

量比：0.72

换手率：0.10%

股息：- -

股息率：- -

每股收益(LYR):-0.454

净资产收益率：-23.27%

总资产收益率：-11.61%

市净率：26.96

市盈率(LYR):-112.93

市销率: - -

数据加载中...

总览公司新闻公告

新股招股｜银诺医药-B今起招股，一手入场费约3773.68港元

老虎资讯综合

8月7日早间银诺医药在港交所公告公司拟全球发售36,556,400股H股香港发售股份3,655,800股国际发售股份32

银诺医药-B(02591.HK)预计8月15日上市引入迈富时等基石

银诺医药-B(02591.HK)8月7日至月12日招股预计8月15日上市

一图解码：减肥药赛道再迎新贵，银诺医药过聆讯，亏损收窄

一周港股IPO：问止中医、欣旺达等7家递表；天岳先进、银诺医药通过聆讯_凤凰网

银诺医药上市聆讯获通过拟于港交所主板上市

中国上市公司网

银诺医药尚无收入商业化临考 IPO前夕股东蹊跷6折转让股权

新股前瞻|核心品种长效化创新优势明显，银诺医药能否靠单品商业化撑起估值？

司美格鲁肽又有新对手！信达生物玛仕度肽获批减重适应症，有诊所预计7日内可发货

国内药企积极布局减肥药领域，又一国产创新药加入对“减肥神药”司美格鲁肽的挑战

华夏时报网

十年烧钱12亿元，银诺医药携“国产司美格鲁肽”二度闯关IPO

微博财经-财道工作室

“国产司美格鲁肽”成业绩“救星”？银诺医药冲刺港股IPO

新股消息 | 银诺医药港股IPO招股书失效

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02591/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"银诺医药－Ｂ","latestPrice":51.3,"timestamp":1756186852073,"preClose":52.6,"halted":0,"volume":416200,"delay":0,"floatShares":420285370,"shares":456819349,"eps":-0.4542803413994238,"marketStatus":"交易中","change":-1.3,"latestTime":"08-26 13:42:30","open":51.5,"high":51.7,"low":50.75,"amount":21292330,"amplitude":0.018061,"askPrice":51.4,"askSize":200,"bidPrice":51.3,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-0.4542803413994238,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1756195800000},"marketStatusCode":2,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":52.6,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":0.720021,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-11.61%","roe":"-23.27%","lyrEps":-0.45428,"volumeRatio":0.720021,"shares":456819349,"dividePrice":0,"high":51.7,"amplitude":0.018061,"preClose":52.6,"low":50.75,"week52Low":49.5,"pbRate":"26.96","week52High":74,"institutionHeld":0,"latestPrice":51.3,"committee":0.333333,"eps":-0.4542803413994238,"divideRate":0,"volume":416200,"delay":0,"ttmEps":-0.4542803413994238,"open":51.5,"prevYearClose":18.68,"prevWeekClose":53,"prevMonthClose":18.68,"prevQuarterClose":18.68,"fiveDayClose":53.85,"twentyDayClose":18.68,"sixtyDayClose":18.68,"earningDate":1756396800000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2025-08-25","current":-125.916102,"percent":1,"low":-137.156472,"twenty":-128.950158,"median":-127.373977,"eighty":-126.160281,"high":-125.916102,"avg":-128.525452,"sd":3.683387,"marketCap":24028697757},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-25","current":-125.916102,"twenty":-128.950158,"median":-127.373977,"eighty":-126.160281,"marketCap":24028697757}],"updateTime":1756186950559},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1111110567","title":"新股招股｜银诺医药-B今起招股，一手入场费约3773.68港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111110567","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111110567?lang=zh_cn&edition=fundamental","pubTime":"2025-08-07 09:34","pubTimestamp":1754530494,"startTime":"0","endTime":"0","summary":"8月7日，$银诺医药-B$于8月7日至8月12日招股，该公司拟全球发售3655.64万股H股，其中香港发售占10%，国际发售占90%。每股发售股份18.68港元。申购阶梯：每手200股，入场费3773.68港元。乙组门槛为30万股，申购所需资金约566.05万港元。集团于2025年1月在中国成功获得用于治疗2型糖尿病的依苏帕格鲁肽α的监管批准。假设发售量调整权及超额配股权未获行使及发售价为每股H股18.68港元，公司的全球发售净所得款项总额将约为6.101亿港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f90b8c761b5eafe71604f7f9c8d19537","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股｜银诺医药-B今起招股，一手入场费约3773.68港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":1},{"id":"2557585987","title":"8月7日早间银诺医药在港交所公告公司拟全球发售36,556,400股H股香港发售股份3,655,800股国际发售股份32","url":"https://stock-news.laohu8.com/highlight/detail?id=2557585987","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557585987?lang=zh_cn&edition=fundamental","pubTime":"2025-08-07 07:27","pubTimestamp":1754522854,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","HEXmain","BK1161","02591","159938","BK1574","BK1515"],"gpt_icon":0},{"id":"2557583771","title":"银诺医药-B(02591.HK)预计8月15日上市 引入迈富时等基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2557583771","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557583771?lang=zh_cn&edition=fundamental","pubTime":"2025-08-07 06:48","pubTimestamp":1754520482,"startTime":"0","endTime":"0","summary":"格隆汇8月7日丨银诺医药-B发布公告，公司拟全球发售3655.64万股H股，中国香港发售股份365.58万股，国际发售股份3290.06万股；2025年8月7日至8月12日招股；发售价将为每股发售股份18.68港元，每手买卖单位为200股，中信证券及中金公司为联席保荐人；预期股份将于2025年8月15日开始在联交所买卖。集团于2025年1月在中国成功获得用于治疗2型糖尿病的依苏帕格鲁肽α的监管批准。截至最后实际可行日期，集团所有的药物及候选药物均由集团自主开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080706480697384ecc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080706480697384ecc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1518","BK1515","09939","02556","BK1161","02591","BK1618","BK1109"],"gpt_icon":1},{"id":"2557585073","title":"银诺医药-B(02591.HK)8月7日至月12日招股 预计8月15日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2557585073","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557585073?lang=zh_cn&edition=fundamental","pubTime":"2025-08-07 06:30","pubTimestamp":1754519402,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["159938","BK1574","BK1515","BK1161","02591","09939"],"gpt_icon":0},{"id":"2557128565","title":"一图解码：减肥药赛道再迎新贵，银诺医药过聆讯 ，亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2557128565","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557128565?lang=zh_cn&edition=fundamental","pubTime":"2025-08-06 09:54","pubTimestamp":1754445253,"startTime":"0","endTime":"0","summary":"近日，银诺医药通过了港交所聆讯，并于7月31日更新了聆讯后招股书，距离挂牌上市只差临门一脚。","market":"other","thumbnail":"https://images.finet.hk/photoLib/title/202508_1/d67c2d51-0158-47d2-9078-7a21efc86f7e.jpg","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202508_1/d67c2d51-0158-47d2-9078-7a21efc86f7e.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/6892b5c55a77128902028476","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["02591"],"gpt_icon":0},{"id":"2556389118","title":"一周港股IPO：问止中医、欣旺达等7家递表；天岳先进、银诺医药通过聆讯_凤凰网","url":"https://stock-news.laohu8.com/highlight/detail?id=2556389118","media":"财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556389118?lang=zh_cn&edition=fundamental","pubTime":"2025-08-04 17:59","pubTimestamp":1754301552,"startTime":"0","endTime":"0","summary":"据港交所披露，上周共有7家公司递表，2家公司通过聆讯；另有1家公司招股，暂无新股上市。业绩方面，2022年至2024年以及2025年截至3月31日止三个月，欣旺达实现收入分别约为521.62亿元、478.62亿元、560.21亿元以及122.89亿元；同期，年/期内利润分别约为7.63亿元、3.31亿元、5.34亿元以及2.99亿元。2）广州银诺医药集团股份有限公司7月31日，银诺医药通过港交所上市聆讯，中信证券和中金公司担任其联席保荐人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080419370794cead47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080419370794cead47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0108","BK0171","02591","BK0072","300207","BK0224","BK0012","BK0214","02631","159938","688234","BK0077","BK0028","BK0155"],"gpt_icon":1},{"id":"2556686926","title":"银诺医药上市聆讯获通过 拟于港交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2556686926","media":"中国上市公司网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556686926?lang=zh_cn&edition=fundamental","pubTime":"2025-08-01 11:25","pubTimestamp":1754018700,"startTime":"0","endTime":"0","summary":"中国上市公司网讯 7月31日，广州银诺医药集团股份有限公司(以下简称“银诺医药”)上市聆讯获通过，公司将登陆港交所主板上市，联席保荐人为中信证券和中金公司。公开数据显示，银诺医药已建 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250801/c670070583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02591","159938"],"gpt_icon":0},{"id":"2549717283","title":"银诺医药尚无收入商业化临考 IPO前夕股东蹊跷6折转让股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2549717283","media":"长江商报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549717283?lang=zh_cn&edition=fundamental","pubTime":"2025-07-07 06:23","pubTimestamp":1751840580,"startTime":"0","endTime":"0","summary":"财务状况显示，银诺医药面临着不小的压力。临近IPO，股东为何会折价卖股？目前来看，银诺医药商业化能力面临大考，并且在持续亏损之下，公司长期依赖外部融资补血。成立至今，银诺医药共进行了四轮融资，融资金额累计15.14亿元。长江商报记者注意到，在银诺医药递表前夕，部分IPO前投资者选择折价转让手中持有的公司股权。此次，银诺医药IPO募资拟主要用于商业化运营及生产建设。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-07/doc-infequmu7957735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","159938","BK1515","02591","BK1161","BK1574"],"gpt_icon":0},{"id":"2548332541","title":"新股前瞻|核心品种长效化创新优势明显，银诺医药能否靠单品商业化撑起估值？","url":"https://stock-news.laohu8.com/highlight/detail?id=2548332541","media":"智通财经","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548332541?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 09:49","pubTimestamp":1751593751,"startTime":"0","endTime":"0","summary":"今年1月，公司核心品种依苏帕格鲁肽α获批上市，用于治疗二型糖尿病。银诺医药也由此结束了自成立以来连续10年零收入的状态。从技术路径角度创新来看，主要分为给药创新和长效化创新，银诺医药的依苏帕格鲁肽α便属于后者。也就是说，尽管增长前景诱人，但GLP-1赛道竞争者如云，虽然目前核心品种顺利上市，但银诺医药距离成功商业化或许还要等一个“完整商业化年度”的业绩验证，而接下来银诺医药要做的便是和时间赛跑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","09939","BK1161","159938","BK1574","BK1515"],"gpt_icon":0},{"id":"2546740195","title":"司美格鲁肽又有新对手！信达生物玛仕度肽获批减重适应症，有诊所预计7日内可发货","url":"https://stock-news.laohu8.com/highlight/detail?id=2546740195","media":"时代财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546740195?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 23:48","pubTimestamp":1751039335,"startTime":"0","endTime":"0","summary":"GLP-1赛道又添一军。6月27日，时代财经从信达生物（01801.HK）获悉，其旗下产品胰高血糖素（GCG）/胰高血糖素样肽-1（GLP-1）双受体激动剂玛仕度肽（商品名：信尔美；研发代号：IBI362）获得国家药品监督管理局（NMPA）批准，用于成人肥胖或超重患者的长期体重控制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506273442788768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1583","LU2328871848.SGD","LU2488822045.USD","01801","02591","BK1589","LU1969619763.USD"],"gpt_icon":0},{"id":"2546920637","title":"国内药企积极布局减肥药领域，又一国产创新药加入对“减肥神药”司美格鲁肽的挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2546920637","media":"华夏时报网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546920637?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 14:51","pubTimestamp":1750920713,"startTime":"0","endTime":"0","summary":"当诺和诺德的司美格鲁肽依旧在减肥药市场横扫天下之时，又一国产 创新药 加入了对司美格鲁肽“药王”地位的挑战。据介绍，埃诺格鲁肽已进入上市申报阶段。在中国减肥药市场，核心份额同样是由诺和诺德和礼来占据，司美格鲁肽2024年在华总销售额达66亿元，新上市的减重版Wegovy 于2025Q1在中国销售额约0.97亿美元。从各家国产创新药产品的临床试验数据来看，不乏可以对原霸主进行挑战的品种。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626145816a71e5b93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626145816a71e5b93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","LU0405327148.USD","LU1997245094.SGD","LU1064131003.USD","02591","LU1997245177.USD","BK0196","BK0028","LU1997244956.HKD","LU1064130708.USD","03692","BK0012","LU2328871848.SGD","BK0060","LU2495084118.USD","LLY","LU2488822045.USD","159992","LU0405327494.USD","LU2148510915.USD","BK0183","BK0239","BK0188","LU1969619763.USD","600276","LU1328615791.USD","LU1655091616.SGD"],"gpt_icon":1},{"id":"2543922546","title":"十年烧钱12亿元，银诺医药携“国产司美格鲁肽”二度闯关IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2543922546","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543922546?lang=zh_cn&edition=fundamental","pubTime":"2025-06-15 16:50","pubTimestamp":1749977400,"startTime":"0","endTime":"0","summary":"研发投入“急刹车”成立于2014年的银诺医药，堪称GLP-1赛道的“长跑选手”。今年1月，用于治疗二型糖尿病的新药依苏帕格鲁肽α获批上市。除已上市的依苏帕格鲁肽α外，用于治疗肥胖和超重以及MASH的依苏帕格鲁肽α于2025年3月启动IIb/III期临床试验，并预计将于2026年第四季度完成该试验。与此同时，诺和诺德司美格鲁肽与礼来替尔泊肽已先后获批减重适应症，同步覆盖糖尿病与减重领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2025-06-15/doc-infaczme4163257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159938","BK1515","BK1574","09939","02591"],"gpt_icon":0},{"id":"2542852135","title":"“国产司美格鲁肽”成业绩“救星”？银诺医药冲刺港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2542852135","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542852135?lang=zh_cn&edition=fundamental","pubTime":"2025-06-11 18:54","pubTimestamp":1749639287,"startTime":"0","endTime":"0","summary":"“国产司美格鲁肽”成业绩“救星”招股书显示，银诺医药成立于2014年，是一家聚焦代谢性疾病领域的创新药企业。凭借超长半衰期和较为优惠的价格，这款药物也被誉为“国产司美格鲁肽”，有望挑战国际巨头的市场地位。此外，银诺医药的行政开支也有较大缩减。银诺医药表示，预计未来几年将继续产生经营亏损。截至2024年12月31日，银诺医药持有的现金及现金等价物为5.27亿元，存在计息银行借款990万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1749638546263839432","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","HSTECH","YANG","02591","BK4614","BK1161","09939","BK1515"],"gpt_icon":1},{"id":"2540719615","title":"新股消息 | 银诺医药港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2540719615","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540719615?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 06:55","pubTimestamp":1748904946,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，广州银诺医药集团股份有限公司于2024年12月3日所递交的港股招股书满6个月，于2025年6月3日失效，递表时中信证券、中金公司为其联席保荐人。招股书显示，银诺医药是亚洲第一家及全球第三家将原研人源长效胰高血糖素样肽-1受体激动剂推进到注册审批阶段的公司。该公司的核心产品依苏帕格鲁肽α即将进入商业化阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1300434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159776","02591"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":54,"code":"91000000","status":"200"}]}}